Erzhi Formula Extracts Reverse Renal Injury in Diabetic Nephropathy Rats by Protecting the Renal Podocytes

الملخص EN

Podocytes injury was a crucial factor resulting in diabetic nephropathy (DN).

Erzhi formula extract (EZF) was a clinical effective Chinese medicine on DN, but its mechanism was unclear.

In this study, the main compounds of EZF and their pharmacokinetics in rat were detected by HPLC-MS/MS.

And then, blood glucose, urine protein, renal index, renal microstructural (HE/PAS staining), inflammatory factors (IL-β, TNF-α, IL-6), and protein/mRNA expression related to the function of podocyte (CD2AP and Podocin) in DN rats were investigated after the oral administration of EZF.

The concentrations of specnuezhenide and wedelolactone in rat kidney were 7.19 and 0.057 mg/kg, respectively.

The Tmax of specnuezhenide and wedelolactone were 2.0 and 1.50 h, respectively.

Their Cmax were, respectively, 30.24 ± 2.68 and 6.39 ± 0.05 μg/L.

Their AUC(0-∞) were 123.30 ± 2.68 and 16.56 ± 0.98 μg/L⁎h, respectively.

Compared with the model group, the blood glucose and the 24-hour urinary protein were significantly decreased (P < 0.05) after 16 weeks’ treatment of EZF.

The expressions of Podocin and CD2AP protein/mRNA were increased (P < 0.

05).

The deteriorate of glomerular morphology was alleviated under the treatment of EZF.

EZF prominently decreased the levels of inflammatory factors (P < 0.05).

MDA was significantly decreased (P < 0.05) with the significant increase of SOD activity (P < 0.05) in EZF groups.

All the results proved that EZF repaired glomerular mesangial matrix, protected renal tubule, and improved renal function in DN rats by upregulating the expression of Podocin and CD2AP protein/mRNA in podocytes.